Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasapaque in Seasonal Allergic Rhinitis
NCT02377895Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Sponsor
- 3E Therapeutics
- Modality
- Small Molecules
- Conditions
- seasonal allergic rhinitis (SAR)
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing Nasapaque with Placebo (2 arms). Primary endpoint: Total Nasal Symptom Score at Day 8. Started Mar 2015; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Nasapaque
Nasapaque Nasal Solution (250 ul)
Placebo
Placebo Saline Nasal Solution (250 ul)
03
Who it enrols
Adult patients with a history of seasonal allergic rhinitis and a positive response to the Allergen BioCube, excluding those with moderate to severe asthma or compromised lung function.
04
Endpoints
Primary
Total Nasal Symptom Score
Secondary
Nasal Inspiratory Flow
Nasal Inflammation Score
Beyond the preview
Go deeper on NCT02377895.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02377895.